Phage Therapy Part A

This book gives a detailed yet clear insight into the current state of the art of the therapeutic application of bacteriophages in different conditions. The authors bring in their practical expertise within their respective fields of expertise and provide an excellent overview of the potential and actual use of phage therapy. Topics like economic feasibility compared to traditional antibiotics and also regulatory issues are discussed in far detail. This new volume is therefore a valuable resource for individuals engaged in the medical application of novel phage therapies.

Phage Therapy - Part A, Volume 200 is an informative text on phage and their use for treatment in bacterial infections. The book highlights a number of aspects of the phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform their research with great interest. Chapters in this new release cover An introduction to bacteriophage and their therapeutic applications, Isolation, screening and characterization of phage, Synthetic phage and their application in phage therapy, Phage engineering for development of diagnostic tools, Phage design and directed evolution to evolve phage for therapy, and more. Additional sections cover Host-phage interactions and modelling for therapy, Phage and phage cocktails formulations, Phage for treatment of Escherichia coli infection, Phage for treatment of Klebsiella pneumoniae infection, Phage for treatment of Salmonella spp infection, Phage for treatment of Staphylococcus aureus infection, and Phages for treatment of Acinetobacter baumannii infection. Includes discussions on phage isolation, screening and characterization Covers synthetic phage, phage for diagnostic, directed evolution and host interaction Presents the latest on phage for treatment of bacterial infections

This book fills a void. Never before has a comprehensive history of phage therapy—a once-neglected, now resurgent field—been written. Kuchment writes from the perspective of the eager student of history for the common reader.

Phage Therapy - Part A, Volume 200 is an informative text on phage and their use for treatment in bacterial infections. The book highlights a number of aspects of the phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform their research with great interest. Chapters in this new release cover An introduction to bacteriophage and their therapeutic applications, Isolation, screening and characterization of phage, Synthetic phage and their application in phage therapy, Phage engineering for development of diagnostic tools, Phage design and directed evolution to evolve phage for therapy, and more. Additional sections cover Host-phage interactions and modelling for therapy, Phage and phage cocktails formulations, Phage for treatment of Escherichia coli infection, Phage for treatment of Klebsiella pneumoniae infection, Phage for treatment of Salmonella spp infection, Phage for treatment of Staphylococcus aureus infection, and Phages for treatment of Acinetobacter baumannii infection.

This volume details the experimental approaches suitable for isolating and characterizing bacteriophages to formulating bacteriophage medicinal products and clinical application. Chapters guide readers through regulatory compliance and safety aspects of bacteriophage therapy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Bacteriophage Therapy: From Lab to Clinical Practice aims to ensure successful results in the further study of this vital field.

Phage Therapy - Part B, Volume 201 covers bacteriophage and their isolation, screening, synthetic phage, diagnostics, directed evolution, host interaction, and more. The book's aim is to highlight a number of aspects of phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform research. Sections cover Phages for the treatment of Pseudomonas aeruginosa infection, Phage for the treatment of Vibrio cholerae infection, Phages for the treatment of Mycobacterium species, Phage therapy for gut microbiome, Phages as delivery vehicles, Phage display, Unlocking the potential of Phages: Innovative Approaches to harnessing Bacteriophages as Diagnostic Tools for Human Diseases, and more. Other sections explore Phage display and human disease detection, Bacteriophage as Cargo and its application in nanomedicine, Phage for drug delivery vehicles, Genome editing for phage design and uses for therapeutic applications, Phage for cancer therapy, and Phage for regenerative medicine and cosmetics. Includes sections on phage isolation, screening and characterization Covers synthetic phage, phage for diagnostic, directed evolution, and host interaction Explores Phage for the treatment of bacterial infections

Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.

This Research Topic is dedicated to Prof. Elisabeth Kutter on the occasion of her 80th birthday. Dr. Kutter’s career as a phage scientist has extended nearly 60 years. She has been a pioneer as a woman in science. She started to work with phage at the University of Rochester, New York working with Dr. Wiberg on radioisotopes making excellent progress in the field – progress which was even cited in Luria’s 1969 Nobel Prize talk. Betty first encountered phage therapy during a visit to Georgia in 1990 which was part of a longer stay in the former Soviet Union under a US-USSR research exchange program. Dr. Kutter was one of the first Americans to advocate for phage therapy in the post antibiotic era. Betty started hosting the Evergreen International Phage meetings in Olympia, Washington, from 1975 onward, which helped to develop a strong phage community with participation increasing over the years to 350 at the 23 rd biannual last year. Betty continues to be an active member in the phage community, sharing her experience and working with all of us toward her ultimate goal of making phage therapy available worldwide thus reducing the burden caused by antibiotic resistant bacterial infections.